Revolutionizing Treatments for Fibrotic Diseases
About
FibroNox
FibroNox has pioneered the development of patented first-in-class treatments to mitigate life-threatening fibrotic diseases. The company has achieved significant milestones by pioneering the development of selective Nox4 inhibitors and Nrf2 activators. In rigorous preclinical studies, FibroNox’s small-molecules have demonstrated robust efficacy for both halting fibrosis and reducing established fibrosis.
These breakthroughs represent a paradigm shifting approach toward more effective strategies to combat fibrotic diseases, as current therapies can only moderately slow disease progression. FibroNox’s is focused on idiopathic pulmonary fibrosis (IPF) as the primary indication, with pre-clinical data to support targeting other fibrotic indications.
New Treatments for Idiopathic Pulmonary Fibrosis are Desperately Needed
Patients in the U.S.
Deaths per year
Median survival
New cases per year
Nintedanib and Pirfenidone
are the Only Two FDA-Approved Treatments
Only slow progression of lung decline
Do not improve the quality of life
Modest survival benefit
50% of patients discontinue treatments*
*Due to adverse effects
Inhaled Therapeutic Delivery for Pulmonary Fibrosis Offers
Significant Advantages
Inhaled delivery of FibroNox’s anti-fibrotic treatments for direct lung-targeting demonstrate robust efficacy at significantly lower dosing than oral delivery in pre-clinical studies. This strategy enables higher drug concentration and increased duration in the lungs with minimal systemic exposure. Overall, inhaled delivery of FibroNox therapeutics for pulmonary fibrosis offers enhanced efficacy significantly reduced potential for off-target and adverse effects.
